SCHEMBL6088005

SCHEMBL6088005

CCOC(=O)/C(C#N)=C1\SCC(=O)N1CCOC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ ATM Q13315 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.43
▸ DHODH Q02127 8/20 0.42
▸ HPGD P15428 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ PKM P14618 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6088011 1.00 MAPT (0.55) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL14574219 0.87 MAPT (0.44) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL3905983 0.86 MAPT (0.48) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL3905980 0.86 MAPT (0.48) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6087029 0.82 MAPT (0.49) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL6087023 0.82 MAPT (0.49) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL6086794 0.79 MAPT (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6086787 0.79 MAPT (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6089701 0.78 MAPT (0.43) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6089707 0.78 MAPT (0.43) MAPTALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors SCHERING AKTIENGESELLSCHAFT 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors PLK4, PLK2, PLK3 MAPT 1138/4885ALDH1A1 2553/4885KMT2A 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback